ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

Abstract

Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

“…This study reviewed and summarized prevention strategies, including screening, monitoring, immunization, prophylaxis, and management of infections associated with about 70 biologic and targeted therapies based on relevant guidelines, especially ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document series published in 2018. [8][9][10][11][12][13] in preventing HBV reactivation in patients on anti-CD20 monoclonal antibodies. 32,33 Therefore, ESCMID recommends either tenofovir or entecavir-based regimens for antiviral therapy in both active and occult hepatitis B patients who are candidates for anti-CD20 targeted agents.…”

“…Pre-emptive antiviral prophylaxis is reasonable in occult HBV infections during treatment with these agents. [8][9][10][11][12][13] The Risk of Pneumocystis Carinii Pneumonia (PCP)…”

“…39 CD22-targeted agents Antiviral treatment is recommended in HBS-Ag positive patients who are candidates for CD-22 targeted agents. 12 Monitoring of HBV viral load is recommended in HBS-Ag negative and anti-HBc-positive patients. 12 CD30-targeted agent Both HBs Ag positive and HBs Ag negative anti-HBc positive patients should receive antiviral prophylaxis before the administration of brentuximab vedotin.…”

“…12 Monitoring of HBV viral load is recommended in HBS-Ag negative and anti-HBc-positive patients. 12 CD30-targeted agent Both HBs Ag positive and HBs Ag negative anti-HBc positive patients should receive antiviral prophylaxis before the administration of brentuximab vedotin. 12 HSV prophylaxis is recommended in patients on brentuximab vedotin.…”

“…The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts Consensus have reviewed articles and made recommendations to instruct clinicians on the strategies to prevent and manage infections associated with biologic and targeted immunomodulators. [8][9][10][11][12][13] In this review, we aim to focus on evidence-based strategies according to the latest guidelines to provide practitioners guidance regarding screening, chemoprophylaxis, vaccination, and management of infections in patients on biologic and targeted immunomodulators.…”